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Abstract
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The hyaluronan receptor for endocytosis (HARE), or Stabilin-2, is the mammalian endocytic
clearance receptor for HA, heparin, advanced glycation end-products, acetylated and oxidized
low-density lipoproteins and collagen N-terminal propeptides. This large 2551 amino acid
receptor is encoded by a gene that covers over 180 kbp on human chromosome 12 and is predicted
to be composed of 69 exons. Due to the expression profile of this gene and the number of exons it
contains, we hypothesized that splice variants of stab2 are encoded in these tissues. In addition, a
correlation between alternative splice variants and cancer progression has been shown in other HA
receptors such as RHAMM and CD42. In this study, two methods were utilized in identifying
and/or isolating the HARE splice variants. The first method used primer sets to amplify the 190HARE encoding region that could contain splice junctions; therefore, they could be removed from
the gel, purified, and sequenced. Five splice variants were detected in that manner. In the second
approach, the entire open reading frame of HARE was amplified. This allowed four splice variants
with extensive exon splicing to be isolated. After the splice variants were sequenced, three were
cloned into a mammalian expression vector. Next, stable cell lines expressing the variants were
created in order to determine stable protein expression. In this study, the splice variants were
found to be tissue specific in most cases. This means that tissue specific regulatory splicing
mechanisms may lead to differences in functionality between the splice variants.

NIH-PA Author Manuscript

Keywords
hyaluronan; receptor; HARE; splice variants; Stabilin-2

© 2014 Elsevier Inc. All rights reserved.
To whom correspondence should be addressed: Edward N. Harris, Department of Biochemistry, University of Nebraska, 1901 Vine
St., Beadle N133, Lincoln, NE 68588, USA, Tel.: 402-472-74686, Fax: 402-472-7842, eharris5@unl.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The authors declare no competing financial interests.

Hare and Harris

Page 2

INTRODUCTION
NIH-PA Author Manuscript

Since the initial purification, identification and molecular cloning of the rat [1, 2, 3] and
human HARE [4, 5], which is also designated Stabilin-2 [6, 7, 8] or FEEL-2 [9], much has
been learned about its ligand binding activities and multiple functions. Although first
identified as the mammalian endocytic clearance receptor for HA and chondroitin sulfates
by Laurent and co-workers [10, 11, 12, 13, 14], HARE/Stab2 is now known to bind >14
distinct ligands, to be a signaling receptor and is involved in a growing list of diverse
physiologic functions. Human HARE/Stab2 is encoded by a 180 kbp gene on chromosome
12q23 consisting of 69 exons, and the full-length 7653 bp mRNA is translated into a 2551 aa
315-kDa Type I glycoprotein receptor, and trafficked to the plasma membrane and
intracellular endosomal compartments. In stably transfected Flp-In 293 cells, 315-kDa
HARE (315-HARE) cDNA is expressed mostly as the full-length polypeptide with a minor
fraction that is post-translationally cleaved to produce a 190-kDa HARE (190-HARE) type I
receptor [15] that is functional in the absence of the 315-HARE [5].
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The 315-HARE and 190-HARE isoforms both bind to HA with high affinity, Kd values of
7–42 nM [15], and mediate very rapid coated pit targeted endocytosis of HA and other
ligands including chondroitin sulfates A, C, D and E, dermatan sulfate, acetylated &
oxidized low density lipoprotein, advanced glycation end-products, and heparin [6, 7, 9, 16,
17, 18, 19, 20]. Both HARE isoforms show HA-dependent intracellular activation of
ERK1/2 [21], which requires the HA-binding Link domain of HARE in its properly
glycosylated state [22]. HARE/Stab2 also binds and mediates phagocytosis of bacteria [9]
and apoptotic cells displaying cell surface phosphatidylserine [23, 24], and mediates
lymphocyte adhesion to sinusoidal endothelium by interacting with αMβ2 [25] and α5β5
integrins [26].
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Over the past 10–15 years, the roles of HA in cancer biology and the importance of tumorassociated alternative splice variants have gained considerable attention. The most studied
HA receptor showing tumor-associated increased transcript diversity for multiple splice
variants is CD44 [27] (e.g. CD44v6 mRNA is increased 82% in colon cancer [28] and
CD44v10 strongly correlates to bladder epithelial carcinoma recurrence [29]). In addition,
up-regulation of RHAMM (Receptor for HA Mediated Mobility) and its variants correlate to
cancer progression [30, 31, 32]. Over-expression of a RHAMMv4 variant, which is
primarily found in the cytoplasm in contrast to the native receptor in the plasma membrane,
promotes cell migration and proliferation via Ras and ERK signaling [33].
Here we report the first identification of nine different tissue-specific splice variants of
human HARE found in cDNA pools of healthy spleen (six), lymph node (three), and bone
marrow (one). Three of these splice variants have been cloned into mammalian-based
vectors for expression in human cell culture.

Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.

Hare and Harris

Page 3

MATERIALS AND METHODS
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Materials and Solutions/Buffers
Flp-In 293 cells, serum, media, Hygromycin B, Zeocin, glutamine, plasmid expression
vectors, and supercompetent TOP10 E. coli, and Lipofectamine2000 were from Invitrogen/
Gibco (Carlsbad, CA). Polyclonal goat anti-V5 affinity purified antibody and goat anti-V5
antibody resin were obtained from Bethyl Labs (Montgomery, TX). All chemical reagents
were purchased for Sigma unless otherwise noted. Buffer compositions may be found in
previous publications [5, 15].
Amplification of variant HARE cDNA species
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Five pairs of primers were used in separate reactions to amplify adjacent ~1 kb regions of
the 190-HARE cDNA (Table I). The cDNA pools used as the source of variant HARE
cDNAs were Marathon-Ready cDNAs (Clontech, now part of Takara Corp.) from human
spleen (Cat. #639312), human lymph node (Cat. #639332), and human bone marrow (Cat.
#639316). In order to detect rarer cDNAs that might require a second round of PCR
amplification, the region immediately below the wildtype band was cut from the gel using a
clean razor blade and nucleic acids were purified from the agarose gel slice using a
GeneClean Turbo kit and subjected to a second round of PCR, with conditions identical to
the first PCR round. Visible bands, stained with ethidium bromide, were excised and
purified with a GeneClean Turbo kit (MPBio) and directly sequenced using the forward
PCR reaction primer. PCR products from reactions containing the ORF flanking primers that
were HARE related and ready for protein expression were immediately cloned into
pcDNA5/FRT/V5-6xHis-TOPO for recombinant protein expression studies.
Transient Transfections
293 Flp-In cells were grown to 50% confluency in DMEM/8% FBS supplement with 100
ug/ml Zeocin in 24 well plates 1 day prior to transfection. For each representative well to be
transfected, 1 μg plasmid DNA was mixed in 50 μl 150 mM NaCl solution pH 7.3 followed
by the addition of 3.3 μl of ExGen500 (Fermentas) and incubated in a 1.5 ml tube for 15
minutes. The entire solution was added to the cells and the plate was centrifuged for 5
minutes at 250×g. Expression of recombinant protein typically took 48 hours.
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Selection and Verification of 35/66 and 13/69 stable cell lines
Cell lines were produced and characterized as described by Harris et al. [5]
Western Blot Assays
Cell lysates, immunoprecipitates using the anti-V5 antibody, or eluate from the nickel
affinity chromatography were mixed with 4x Laemmli sample buffer without reducing agent
and analyzed by a 5% or 10% SDS-PAGE gel.

RESULTS
The full-length hare mRNA contains 69 exons, which are remarkably similar in size (46 to
197 bp) as predicted by the NCBI database (Accession #NM_017564, supplemental Figure
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1). We employed two strategies to amplify low-copy spliced cDNAs from Marathon human
cDNA pools from both spleen and lymph node. For our first strategy, we used 5 primer sets
(Table 1) encompassing the 190-HARE encoding region to amplify regions of <1100 bp that
may have only one exon excision (Figure 1a). This was performed to have a control for each
primer set in the amplification reaction as well as amplifying a region small enough so that a
transcript with an exon deletion could be detected by separation on agarose gel
electrophoresis. The control reaction contained only the recombinant 190-HARE cDNA so
that the abundant wildtype cDNA in the Marathon pools could be identified and separated
from any splice variants. All of the reactions were separated by 1% gel electrophoresis
(Figure 1b). Since any potential splice variants would be smaller than wildtype, we excised
the region below the wildtype band with a razor blade, purified all nucleic acids from the
gel, and repeated the amplification reaction. The second reaction produced one to several
bands in 3 of the 4 lanes that were not seen from the first reaction (Figure 1c). Each DNA
band was purified from the gel and sequenced. Some bands were the result of non-STAB2
gene specific primer annealing to cDNAs that encoded enzymes in other metabolic
pathways. However, the brightest of the bands in the 2nd amplification reactions usually
were splice variants for HARE (Figure 1c). Some of the splice variants were of sufficiently
high copy number to detect from the initial amplification reaction (Figure 1d, gray arrow)
and distinguished from the wildtype copy (Figure 1d, black arrow).
Our second strategy was to use a primer set that flanked and amplified the entire open
reading frame for STAB2 in spleen, lymph node, and bone marrow cDNA pools. This
method was used to identify and isolate four splice variants with extensive exon splicing in
addition to obtaining a cDNA that could be expressed in 293 Flp-In cell lines. In most cases,
the splice variants were tissue specific. Using the same amplification reactions outlined
above in spleen, lymph node, and bone marrow cDNA pools, we identified the presence of
one of the variants in either spleen (Figure 1d) or in lymph node, but not in both. This was
true for all but one of the variants (35/66, found in LN and BM) leading us to believe that
there are different tissue specific regulatory splicing mechanisms employed and that the
splice variants may be functionally unique (Figure 1e). Table 2 gives more details for each
splice variant discovered to date.
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To name the splice variants, we used the backslash (/) to indicate the region that was spliced
out of the original transcript. For example, variant 1/63 is missing exons 2–62 and exons 1
and 63 are fused in frame. A schematic representation of all the splice variants is illustrated
in Figure 2. The first four variants contain the entire open reading frame and three of these
were expressed in mammalian cells. The remaining five variants consist of regions that were
identified by the flanking primers outlined in the first amplification strategy and are partial
sequences of the variant. The yellow boxes represent frame shifts due to the exon fusion in
the splicing region of the DNA that resulted in a premature stop codon. The arrows indicate
the areas in which the remaining splice variant cDNA would presumably exist, but remains
unidentified due to the limitations imposed by the first strategy.

Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.

Hare and Harris

Page 5

Splice variants are stably expressed in cell culture
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After the sequence was confirmed, the cDNAs for variants 1/63, 13/69, and 35/66 were
cloned into the mammalian expression vector, pcDNA5/FRT/V5-6xHis-TOPO which is
suitable for both transient and stable transfections. This procedure was performed to ensure
that the protein was folded and expressed in the correct manner as previous attempts to clone
deletion mutants of HARE were quickly degraded, probably as a result of misfolding, and
not expressed in cell lines. Three splice variants were expressed in transient transfections
and detected with the anti-V5 antibody. Stable cell lines expressing these variants were
created to determine stable protein expression. In Figure 3a, variant 1/63 (gray arrow) is
membrane bound in contrast to variant 13/69 (black arrow) which is secreted from the cells.
Both variants were immunoprecipitated with the anti-V5 antibody resin, separated by 10%
SDS-PAGE, and detected with anti-V5 antibody. In Figure 3b, variant 35/66 is also
membrane-bound and cell lysates from wildtype (black arrow) and 35/66 stable clone 8
(gray arrow) were separated by 5% SDS-PAGE and detected by anti-V5 antibody.
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Three of the eight monoclonals raised against the rat 175-kDa HARE protein cross-react
with both isoforms of wildtype human HARE [5, 15]. Cell lysates from stably expressing
35/66 cell lines were tested against mAbs 30, 154, and 159 (Fig. 4a). Only mAb159 reacted
against multiple clones of variant 35/66 (Figure 4b) as compared against the control
antibody, anti-V5 (Figure 4c). Variants 1/63 and 13/69 did not react with any of the mAbs
(not shown). This data, in conjunction with other unpublished data from our laboratory,
suggests that antibody 159 recognizes an epitope, which is very close to the transmembrane
region and most likely located within exon 66.

DISCUSSION
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Regulation of post-translational processes in different tissues may affect how HARE binds
to HA and other GAGs. This may also apply to post-transcriptional modification of the
HARE mRNA where numerous splice variants may be expressed differentially in normal
tissues or altered in cancerous cells. Although previous experiments using anti-HARE mAb
to evaluate HARE-related protein expression were negative for most rat tissues tested, the
lack of antibody reactivity for smaller splice variants may be due to lower expression levels
of the protein or to missing epitopes in the expressed splice variants [1]. Additional studies
confirm that stab2 mRNA is present in liver, spleen [8] and in bone marrow [34].
The human stab2 gene annotation in the NCBI database predicts 69 exons in which the
sequences of the exon-exon linkages are predicted. The presence of these splice variants in
normal tissue used to produce the cDNA pools do not seem to be a result of random
ligations or a product of the experimental procedures. The chosen primers merely amplified
the region of interest without manipulating the DNA. How do we know that these splice
variants are real and not a result of the procedure? First, all but one of the splice variants
were spliced at the predicted junctions. The only variant that did not adhere to this parameter
was HAREv(62/67) in which the last 9 codons of exon 62 were lost and most of the codons
on the 5’ half of exon 67 were also lost to form a hybrid region composing of exons 62 and
67 linked in frame. Theoretically, the resulting protein would be secreted since the
transmembrane domain, which is encoded mostly by exon 67, is lost. The second line of
Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.
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evidence which demonstrates that the formation of HARE splice variants are a real
biological process is that HAREv(35/66) has two isoforms on the RNA level encoding the
same predicted protein. Version 1 of this variant adheres strictly to the predicted joining of
exons 35 and 66 through the pairing of two adenosines. In contrast, version 2 loses the
terminal adenosine on exon 35 and gains a terminal guanidine on exon 65 resulting in the
pairing of two guanidines and preserving the reading frame (Supplemental Figure 2). Both
splicing versions of HAREv(35/66) produce a translated product with version 1 used in the
experimental procedures of this paper.
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The full-length HARE protein contains 204 cysteine amino acid of which over half are
known to fold in 21 EGF/EGF-like domains organized in 4 clusters and one Link domain
near the transmembrane domain. The remaining 74 cysteine residues are thought to be
participating in either disulfide bonds with each other or modified in various forms of
cysteine oxidation due to the oxidizing conditions found in the ER [35]. The best engineered
E. coli strains designed specifically for protein folding do not match the fidelity of the
mammalian ER calnexin/calreticulin system for HARE expression [25, 36]. Thus, an
improperly folded HARE protein does not progress to the Golgi and is degraded through the
ERAD system [37]. Since the overall physical structure and cysteine bonding pattern is not
established for HARE or for Stabilin-1, the closest orthologue of HARE, the construction of
deletion mutants using the exon junctions have proven quite advantageous when evaluating
specific domains.
The majority of the protein comprising v35/66 (exons 1–35/66–69), is absent from the 190HARE isoform (exons 32–69). We had previously tested both 190- and 315-HARE isoforms
for a number of ligands to determine binding sites. Hyaluronan, CS-A, CS-C, and CS-D all
bind within the Link domain (green region, Fig. 2) and heparin and acetylated LDL strictly
bind to a region upstream of the Link domain [16]. Since the heparin binding site(s) have not
been elucidated, we set out to determine if v35/66 may contain one or more of these sites.
Through numerous binding and endocytosis assays, it was determined that v35/66 does not
bind heparin; therefore, the heparin-binding site(s) are situated all within the 190-HARE
protein (data not shown). This further confirms our previous data which demonstrated that
both HARE/Stab2 isoforms have approximately the same binding constants and capacity for
heparin ligands [17].
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Further studies are needed to define the physiological function of these splice variants and to
screen malignant tissues to determine if there is a differential expression compared to
healthy tissue.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
HA

Hyaluronic Acid

HARE

Hyaluronic Acid Receptor for Endocytosis

190-HARE

the small isoform of HARE

315-HARE

the full-length isoform of HARE

hnRNA

heteronuclear RNA

mAb

monoclonal antibody

NCBI

National Center for Biotechnology Information

References

NIH-PA Author Manuscript
NIH-PA Author Manuscript

1. Zhou B, Weigel JA, Fauss L, Weigel PH. Identification of the hyaluronan receptor for endocytosis
(HARE). J Biol Chem. 2000; 275:37733–37741. [PubMed: 10952975]
2. Zhou B, Weigel JA, Saxena A, Weigel PH. Molecular cloning and functional expression of the rat
175-kDa hyaluronan receptor for endocytosis. Mol Biol Cell. 2002; 13:2853–2868. [PubMed:
12181351]
3. Zhou B, Oka JA, Singh A, Weigel PH. Purification and subunit characterization of the rat liver
endocytic hyaluronan receptor. J Biol Chem. 1999; 274:33831–33834. [PubMed: 10567337]
4. Zhou B, McGary CT, Weigel JA, Saxena A, Weigel PH. Purification and molecular identification of
the human hyaluronan receptor for endocytosis. Glycobiology. 2003; 13:339–349. [PubMed:
12626425]
5. Harris EN, Weigel JA, Weigel PH. Endocytic function, glycosaminoglycan specificity, and antibody
sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE). J Biol
Chem. 2004; 279:36201–36209. [PubMed: 15208308]
6. Hansen B, Longati P, Elvevold K, Nedredal GI, Schledzewski K, Olsen R, Falkowski M,
Kzhyshkowska J, Carlsson F, Johansson S, Smedsrod B, Goerdt S, McCourt P. Stabilin-1 and
stabilin-2 are both directed into the early endocytic pathway in hepatic sinusoidal endothelium via
interactions with clathrin/AP-2, independent of ligand binding. Exp Cell Res. 2005; 303:160–173.
[PubMed: 15572036]
7. Politz O, Gratchev A, McCourt PA, Schledzewski K, Guillot P, Johansson S, Svineng G, Franke P,
Kannicht C, Kzhyshkowska J, Longati P, Velten FW, Goerdt S. Stabilin-1 and-2 constitute a novel
family of fasciclin-like hyaluronan receptor homologues. Biochem J. 2002; 362:155–164. [PubMed:
11829752]
8. Falkowski M, Schledzewski K, Hansen B, Goerdt S. Expression of stabilin-2, a novel fasciclin-like
hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid
interfaces. Histochem Cell Biol. 2003; 120:361–369. [PubMed: 14598175]
9. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita S, Iizuka Y,
Shimano H, Nagai R, Kimura S, Tsujimoto M, Ishibashi S. FEEL-1 and FEEL-2 are endocytic
receptors for advanced glycation end products. J Biol Chem. 2003; 278:12613–12617. [PubMed:
12473645]
10. Smedsrod B, Malmgren M, Ericsson J, Laurent TC. Morphological studies on endocytosis of
chondroitin sulphate proteoglycan by rat liver endothelial cells. Cell Tissue Res. 1988; 253:39–45.
[PubMed: 3416346]
11. Laurent TC, Fraser JR, Pertoft H, Smedsrod B. Binding of hyaluronate and chondroitin sulphate to
liver endothelial cells. Biochem J. 1986; 234:653–658. [PubMed: 3087347]

Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.

Hare and Harris

Page 8

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

12. Eriksson S, Fraser JR, Laurent TC, Pertoft H, Smedsrod B. Endothelial cells are a site of uptake
and degradation of hyaluronic acid in the liver. Exp Cell Res. 1983; 144:223–228. [PubMed:
6840207]
13. Fraser JR, Appelgren LE, Laurent TC. Tissue uptake of circulating hyaluronic acid. A whole body
autoradiographic study. Cell Tissue Res. 1983; 233:285–293. [PubMed: 6413068]
14. Fraser JR, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism
of hyaluronic acid injected intravenously in the rabbit. Biochem J. 1981; 200:415–424. [PubMed:
7340841]
15. Harris EN, Kyosseva SV, Weigel JA, Weigel PH. Expression, processing, and glycosaminoglycan
binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis
(HARE). J Biol Chem. 2007; 282:2785–2797. [PubMed: 17145755]
16. Harris EN, Weigel PH. The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates
A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density
lipoprotein, dermatan sulfate, and CS-E. Glycobiology. 2008; 18:638–648. [PubMed: 18499864]
17. Harris EN, Weigel JA, Weigel PH. The human hyaluronan receptor for endocytosis (HARE/
Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem. 2008; 283:17341–17350.
[PubMed: 18434317]
18. Harris EN, Baggenstoss BA, Weigel PH. Rat and human HARE/stabilin-2 are clearance receptors
for high- and low-molecular-weight heparins. Am J Physiol Gastrointest Liver Physiol. 2009;
296:G1191–G1199. [PubMed: 19359419]
19. Li R, Oteiza A, Sorensen KK, McCourt P, Olsen R, Smedsrod B, Svistounov D. Role of liver
sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J
Physiol Gastrointest Liver Physiol. 2011; 300:G71–G81. [PubMed: 21030611]
20. Hansen B, Svistounov D, Olsen R, Nagai R, Horiuchi S, Smedsrod B. Advanced glycation end
products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia.
2002; 45:1379–1388. [PubMed: 12378378]
21. Kyosseva SV, Harris EN, Weigel PH. The hyaluronan receptor for endocytosis mediates
hyaluronan-dependent signal transduction via extracellular signal-regulated kinases. J Biol Chem.
2008; 283:15047–15055. [PubMed: 18387958]
22. Pandey MS, Weigel PH. Hyaluronic Acid Receptor for Endocytosis (HARE)-Mediated
Endocytosis of Hyaluronan, Heparin, Dermatan Sulfate and Acetylated LDL, but not Chondroitin
Sulfate Types A, C, D or E Activates NF-kB-Regulated Gene Expression. J Biol Chem. 2014;
289:1756–1767. [PubMed: 24247245]
23. Park SY, Kim SY, Jung MY, Bae DJ, Kim IS. Epidermal growth factor-like domain repeat of
stabilin-2 recognizes phosphatidylserine during cell corpse clearance. Mol Cell Biol. 2008;
28:5288–5298. [PubMed: 18573870]
24. Park SY, Jung MY, Kim HJ, Lee SJ, Kim SY, Lee BH, Kwon TH, Park RW, Kim IS. Rapid cell
corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 2008;
15:192–201. [PubMed: 17962816]
25. Jung MY, Park SY, Kim IS. Stabilin-2 is involved in lymphocyte adhesion to the hepatic
sinusoidal endothelium via the interaction with alphaMbeta2 integrin. J Leukoc Biol. 2007;
82:1156–1165. [PubMed: 17675564]
26. Kim S, Park SY, Kim SY, Bae DJ, Pyo JH, Hong M, Kim IS. Cross-talk between engulfment
receptors, stabilin-2 and integrin alphavbeta5 orchestrates engulfment of phosphatidylserine
exposed erythrocytes. Mol Cell Biol. 2012
27. Banky B, Raso-Barnett L, Barbai T, Timar J, Becsagh P, Raso E. Characteristics of CD44
alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol
Cancer. 2012; 11:83. [PubMed: 23151220]
28. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Tohnai I, Ueda M, Kimata K.
CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time
reverse transcriptase-polymerase chain reaction. Oncol Rep. 2003; 10:1919–1924. [PubMed:
14534719]

Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.

Hare and Harris

Page 9

NIH-PA Author Manuscript
NIH-PA Author Manuscript

29. Chuang CK, Liao SK. Differential expression of CD44 variant isoforms by cell lines and tissue
specimens of transitional cell carcinomas. Anticancer Res. 2003; 23:4635–4639. [PubMed:
14981907]
30. Villegas-Ruiz V, Salcedo M, Zentella-Dehesa A, de Oca EV, Roman-Basaure E, Mantilla-Morales
A, Davila-Borja VM, Juarez-Mendez S. A case of cervical cancer expressed three mRNA variant
of Hyaluronan-mediated motility receptor. Int J Clin Exp Pathol. 2014; 7:2256–2264. [PubMed:
24966934]
31. Li H, Guo L, Li JW, Liu N, Qi R, Liu J. Expression of hyaluronan receptors CD44 and RHAMM
in stomach cancers: relevance with tumor progression. Int J Oncol. 2000; 17:927–932. [PubMed:
11029494]
32. Li H, Guo L, Li J, Liu N, Liu J. Alternative splicing of RHAMM gene in chinese gastric cancers
and its in vitro regulation. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2000; 17:343–347. [PubMed:
11024216]
33. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA. The hyaluronan receptor
RHAMM regulates extracellular-regulated kinase. J Biol Chem. 1998; 273:11342–11348.
[PubMed: 9556628]
34. Qian H, Johansson S, McCourt P, Smedsrod B, Ekblom M. Stabilins are expressed in bone marrow
sinusoidal endothelial cells and mediate scavenging and cell adhesive functions. Biochem Biophys
Res Commun. 2009; 390:883–886. [PubMed: 19850011]
35. Reddie KG, Carroll KS. Expanding the functional diversity of proteins through cysteine oxidation.
Curr Opin Chem Biol. 2008; 12:746–754. [PubMed: 18804173]
36. Benham AM. Protein secretion and the endoplasmic reticulum. Cold Spring Harb Perspect Biol.
2012; 4:1–16.
37. Lemus L, Goder V. Regulation of Endoplasmic Reticulum-Associated Protein Degradation
(ERAD) by Ubiquitin. Cells. 2014; 3:824–847. [PubMed: 25100021]

NIH-PA Author Manuscript
Biochem Biophys Res Commun. Author manuscript; available in PMC 2016 January 02.

Hare and Harris

Page 10

NIH-PA Author Manuscript

•

HARE has 69 exons.

•

Nine splice variants were detected by PCR.

•

HARE undergoes specific splicing.
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FIGURE 1.

Strategy for identifying and cloning splice variants from human cDNA pools. A) Regions of
the 190-HARE targeted for amplification. B) The agarose gel indicating both control (lanes
marked with “c”) and samples. The “+” is the positive GAPDH control for the PCR
conditions with the cDNA pools. The white boxes indicate areas of the gel that were cut out
with a standard razor blade and purified for nucleic acids. C) Re-amplification results from
areas cut from the gel as indicated in part B. D) Flanking primers for HARE in both lymph
node and spleen cDNA pools. The black arrow indicates the WT cDNA product and the
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gray arrow indicates the splice variant. E) Side-by-side comparison of the PCR results on
agarose gel of the bone marrow and lymph node cDNA pools using HARE flanking primers.
Black arrow = WT, gray arrows = potential splice variants.
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FIGURE 2.

An illustration of the HARE splice variants identified to date. Each rectangle represents an
exon. Red = EGF/EGF-like clusters, white = Fasciclin domains, green = Link domain, blue
= transmembrane domain, purple = cytoplasmic domain, yellow = newly translated portion
of a variant caused by a frameshift at the splice junction.
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FIGURE 3.
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Expression of splice variants in stable cell lines. A) Immunoprecipitation followed by 10%
SDS-PAGE, blotting, and probing with anti-V5 of HAREv1/63 (lane 1) and HAREv13/69
(lane 2) in addition to anti-V5 resin alone (lane 3). Arrows indicate the respective
recombinant proteins. B) Cell lysates from WT (lane 1) and HAREv35/66 (lane 2) are
separated by 5% SDS-PAGE, blotted and probed with anti-V5.
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FIGURE 4.

HAREv35/66 reacts with anti-rat HARE mAb159. A) The three monoclonal antibodies (30,
154, 159) that react with human HARE were also reacted against HAREv35/66 cell lysate.
Cell lysates from the following cell lines (lane 1=190-HARE, lane 2 = HAREv35/66 clone
5, lane 3 = clone 8, lane 4 = clone 13, lane 5 = clone 18) were probed with B) mAb159 and
C) anti-V5.
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190-HARE Primers used to amplify variants
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The five overlapping sets (numbered 1–5) of forward (F) and reverse (R) primers spanning the complete 190HARE ORF cDNA sequence (amplified using the last primer pair) are indicated in the schematic in Fig. 1.
The numbering for the starting 5’ nucleotide in each primer is based on the full-length 315-HARE coding
sequence.
Primer Set

Tm
(°C)
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Primer start
nucleotide
number

Primer Sequence

1

65

F:3406
R:3711

F: 5’-TTCGAATCCTTACCAAACCTGCTCATGCG
R: 5’-GTCATTATGGAGAAAGAAGCTCAGGAAATAGGAGAAACC

2

65

F:3673
R:4890

F: 5’-GGTTTCTCCTATTTCCTGAGCTTCTTTCTCCATAATGAC
R: 5’-GAAGGGGCCCGGTCCGACCAGATCTTTCAC

3

70

F:4861
R:5520

F: 5’-GTGAAAGATCTGGTCGGACCGGGCCCCTTC
R: 5’-CAGCTCTGAACCCTGCAGGGTCTTCCAGGC

4

65

F:5491
R:6621

F: 5’-GCCTGGAAGACCCTGCAGGGTTCAGAGCTG
R: 5’-GCCCAGTGGCGATCGTAGATGGAACAC

5

65

F:6595
R:7653

F: 5’-GTGTTCCATCTACGATCGCCACTGGGC
R: 5’-CGGGATCCCAGTGTCCTCAAGGGGTCATTG

315-HARE
ORF

62

F:1
R:7653

F: 5’-CGGGATCCATGATGCTACAACATTTAGTAATTTTTTGTCTTGG
R: 5’-CGGGATCCCAGTGTCCTCAAGGGGTCATTG
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2–63
14–68
2–62
36–65
59

hHAREv(1/64)

hHAREv(13/69)

HHAREv(1/63)

hHAREv(35/66)

hHAREv(58/60)fs

Yes

No

No

No

No

No

No

Yes

Yes

Frameshift

splice variant that does not follow splicing rules.

*

59,60
63–66

38

hHAREv(37/39)fs

hHAREv(~62/67)*

63

hHAREv(62/64)fs

hHAREv(58/61)

Exon(s)
spliced out

Name of Variant

No

Yes

Yes

Yes

Yes

No

No

No

No

Inclusion of
full reading
ORF

LN

LN/BM

LN

Spleen

Spleen

Spleen

Spleen

Spleen

Spleen

Resident
Organ

No

Yes

Yes

Yes

Yes

No

No

No

Yes

Detected in
first round of
PCR

Splice variants identified from human spleen and lymph node cDNA pools.
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